Quarterly Net Profit at Rs. 50.00 crore in March 2025 down 20.26% from Rs. 62.70 crore in March 2024. EBITDA stands at Rs. 69 ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.